LVTX - LAVA Therapeutics N.V. Price to Earnings Adjusted for Growth Rate

Corporate company logo of LAVA Therapeutics N.V. (LVTX)

The lack of commercial profit forces LAVA Therapeutics N.V. (LVTX) to strictly control its capital expenditure. The current P/E to growth trend illustrates this dependency, where 0.00 reflects the latest value of the metric. The brand's resilience is based on its scientific reputation for developing selective gamma-delta T-cell therapies. Further success depends on the efficacy of clinical trials and the support of specialized partners.

LVTX: Lava Tx PEG Multiple 07/04/2022 - 12/06/2025

Metric breakdowns and analytics for LAVA Therapeutics NV (LVTX)

- market value and analyst target forecast:
Summary company analytics:LVTX LAVA Therapeutics N.V.
Original product of LAVA Therapeutics

LAVA Therapeutics N.V. (LVTX) is developing innovative pre-commercial oncology drugs with colossal market potential. The PEG ratio correlates the current P/E multiple with expected earnings growth rates, adjusting the company's valuation to account for its expansion. Investors utilize this balance to identify undervalued assets with high capitalization potential. Values below one signal promising growth. By analyzing the PEG ratio's dynamics, one can determine the optimal moment for capital allocation.

Competitors of LAVA Therapeutics N.V.

ImmunityBio, Inc. (IBRX) - Price to Net Income Growth Ratio|Immunocore Holdings - Price/Earnings to Growth Multiple|Janux Therapeutics, Inc. (JANX) - Price to Earnings Adjusted for Growth Rate|RCUS: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio ZYME (Zymeworks)|TNGX: PEG Multiple|IOVA - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio immatics.com|Price/Earnings to Growth Multiple xencor.com (XNCR)|Price/Earnings to Growth Ratio Compass Therapeutics Inc (CMPX)|Price/Earnings to Growth Multiple Replimune Corp REPL|Lyell - Price/Earnings to Growth Multiple|PEG Multiple Innate Pharma S.A IPHA|PYXS - Price/Earnings to Growth Ratio|CGEN (Compugen) - Growth-Adjusted P/E Ratio|IO Biotech Inc. (IOBT) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Sutro Bio (STRO)|Price/Earnings to Growth Multiple INKT|HOWL - Price to Net Income Growth Ratio|Price/Earnings to Growth Multiple IMMX (Immix Biopharma, Inc.)|Company Value to Earnings Growth Ratio ALXO|PEG Multiple CUE (Cue Biopharma Inc.)|Growth-Adjusted Payback Ratio PDSB|Sonnet BioTherapeutics Holdings Inc. - PEG Multiple|Price to Earnings Adjusted for Growth Rate MAIA Bio|Liminatus Pharma (LIMN) - Price/Earnings to Growth Ratio|NextCure, Inc. - Growth-Adjusted Payback Ratio|LPTX (Leap Tx) - PEG Multiple|PEG Multiple intensitytherapeutics.com|Price/Earnings to Growth Ratio senseibio.com (SNSE)|TOVX: Market Cap to Earnings and Growth Ratio|Gritstone bio - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income kinetabio.com (KA)|NEXI - Price/Earnings to Growth Ratio|Turnstone Biologics Corp - Company Value to Earnings Growth Ratio|VCNX: PEG Multiple|Harpoon Therapeutics Corp (HARP) - PEG Multiple